CDX2: Linking Cell and Patient Fates in Colon Cancer

Eric R. Fearon; Emina H. Huang

doi:10.1016/j.stem.2016.01.011

CDX2: Linking Cell and Patient Fates in Colon Cancer

Eric R. Fearon, Emina H. Huang

Research output: Contribution to journal › Short survey › peer-review

4 Scopus citations

Abstract

Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.

Original language	English (US)
Pages (from-to)	168-169
Number of pages	2
Journal	Cell Stem Cell
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.stem.2016.01.011
State	Published - Feb 4 2016
Externally published	Yes

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

Access to Document

10.1016/j.stem.2016.01.011

Cite this

@article{bc622b6e97ac4c578ca5a49c17958c62,

title = "CDX2: Linking Cell and Patient Fates in Colon Cancer",

abstract = "Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.",

author = "Fearon, {Eric R.} and Huang, {Emina H.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = feb,

day = "4",

doi = "10.1016/j.stem.2016.01.011",

language = "English (US)",

volume = "18",

pages = "168--169",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - CDX2

T2 - Linking Cell and Patient Fates in Colon Cancer

AU - Fearon, Eric R.

AU - Huang, Emina H.

PY - 2016/2/4

Y1 - 2016/2/4

N2 - Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.

AB - Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.

UR - http://www.scopus.com/inward/record.url?scp=84957872720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957872720&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2016.01.011

DO - 10.1016/j.stem.2016.01.011

M3 - Short survey

C2 - 26849302

AN - SCOPUS:84957872720

SN - 1934-5909

VL - 18

SP - 168

EP - 169

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 2

ER -

CDX2: Linking Cell and Patient Fates in Colon Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this